摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-二噁烷-5-羧酸甲酯 | 190191-69-6

中文名称
1,3-二噁烷-5-羧酸甲酯
中文别名
——
英文名称
Methyl 1,3-dioxane-5-carboxylate
英文别名
——
1,3-二噁烷-5-羧酸甲酯化学式
CAS
190191-69-6
化学式
C6H10O4
mdl
——
分子量
146.14
InChiKey
VLMXHXVWOSBWTO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    177.5±25.0 °C(Predicted)
  • 密度:
    1.158±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090

文献信息

  • [EN] NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE 1,3-OXAZOLIDINE ET UTILISATION DE CES DERNIERS COMME INHIBITEURS DE LA RÉNINE
    申请人:NOVADEX PHARMACEUTICALS AB
    公开号:WO2011056126A1
    公开(公告)日:2011-05-12
    The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.
    本发明涉及某些新颖的1,3-噁唑烷化合物(I)的公式,以及制备这类化合物的方法,以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。
  • SUBSTITUTED CYCLOALKENE DERIVATIVE
    申请人:Kimura Tomio
    公开号:US20090233952A1
    公开(公告)日:2009-09-17
    [Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation. [Solution] A compound represented by the general formula (I): wherein X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B. l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3. R 1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3. R 2 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. R 3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε. R 5 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. Provided that in the case where R 3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.
    [目的] 提供一种替代环烯烃衍生物,具有抑制内毒素诱导的细胞内信号传导或细胞活化并抑制细胞对细胞内信号传导和细胞活化的反应,例如过量生成TNF-α等炎症介质,其药理学上可接受的盐,包含其作为活性成分的药物,其制备方法以及含有上述替代环烯烃衍生物作为活性成分的药物,其在预防和/或治疗与内毒素诱导的细胞内信号传导或细胞活化以及对细胞内信号传导和细胞活化的反应有关的疾病,例如败血症(败血性休克,弥漫性血管内凝血,多器官衰竭等)方面具有优越性。 [解决方案] 一种由通式(I)表示的化合物:其中,X和Y表示与它们结合的碳原子形成环A(环为3-至7成员的杂环或3-至7成员的环烷基环)的基团,每个表示氢原子,或X和Y一起表示环B的取代基。l和m,独立地,表示0至3的整数,且l+m为1至3。R1是脂肪烃基等,可以被从取代基组β和取代基组γ中选择的基团取代。n表示0至3的整数。R2是C1-C6烷基等,可以被从氢原子和取代基组β中选择的基团取代。R3是苯基,5-至6成员的杂环基等,可以被从取代基组ε中选择的基团取代。R5是C1-C6烷基等,可以被从氢原子和取代基组β中选择的基团取代。但在R3是苯基且可以被从取代基组ε中选择的基团取代的情况下,X和Y表示与它们结合的碳原子形成环A的基团,或X和Y一起表示环B的取代基。
  • NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS
    申请人:Sun Piaoyang
    公开号:US20130005730A1
    公开(公告)日:2013-01-03
    The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.
    本发明涉及一些新型1,3-噁唑啉化合物(I)的公式,制备这些化合物的方法以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。
  • US7935835B2
    申请人:——
    公开号:US7935835B2
    公开(公告)日:2011-05-03
  • USRE43858E1
    申请人:——
    公开号:USRE43858E1
    公开(公告)日:2012-12-11
查看更多

同类化合物

(2S,4aR,5S,8R,8aR)-8-乙基-4a,5-二羟基-六氢-2H-2,5-环氧色素-4(3H)-酮 阿斯利多 锗(II)氯化二噁烷络合物 试剂5-Methyl-5-propargyloxycarbonyl-1,3-dioxane-2-one 螺二醇 螺[环丙烷-1,7'-[2,3]二氧杂双环[2.2.1]庚烷] 螺[3,6-二氧杂双环[3.1.0]己烷-2,4'-咪唑烷] 薰衣草恶烷 苯乙醛 1,3-丙烷二基缩醛 脱水莫诺苷元 硫脲与2,4,8,10-四氧杂螺[5.5]十一烷-3,9-丙二胺和缩水甘油丁醚的反应产物 硝溴生 盐酸大观霉素 盐酸1,4-二恶烷 甲基 2,3-脱水-beta-D-呋喃核糖苷 甘油缩甲醛 溴化[5-(羟甲基)-2-苯基-1,3-二噁烷-5-基]-N,N,N-三甲基甲铵 溴[4-(1,3-二恶烷-2-基)苯基]镁 溴[3-(1,3-二恶烷-2-基)苯基]镁 溴[2-(1,3-二恶烷-2-基)苯基]镁 溴-1,4-二氧六环复合物 氯甲基聚苯乙烯 敌噁磷 戊氧氯醛 对二恶烷-2,6-二甲醇 奇烯醇霉素 大观霉素 埃玛菌素 吡啶,2-(1,3-二噁烷-2-基)- 反式-5-溴-4-苯基-[1,3]二恶烷 反式-2,5-双-(羟甲基)-1,4-二恶烷 双(4-乙基亚苯基)山梨醇 六氢[1,4]二恶英并[2,3-b]-1,4-二恶英 六氢-2,4,4,7-四甲基-4H-1,3-苯并二氧杂环己 全氟(2-氧代-3,6-二甲基-1,4-二恶烷) 亚苄基-2,2-双(氧基甲基)丙酸 二苯并[b,e][1,4]二噁英,4a,5a,9a,10a-四氢-,溴化氯化(1:2:6) 二苯并[b,e][1,4]二噁英,4a,5a,9a,10a-四氢-,溴化氯化(1:2:5) 二聚丁醇醛 二甲基二恶烷 二甲基2,4:3,5-二-O-亚甲基-D-葡萄糖二酸 二甲基2,4,8,10-四氧杂螺[5.5]十一烷-3,9-二羧酸酯 二甲基-1,4-二恶烷 二甘醇酐 二环[3.1.0]己烷-3-酮,4-亚甲基-1-(1-甲基乙基)-,肟 二氯硼烷二氧六环 二氧六环-d8 二氢壮观霉素 二恶烷 二噁烷甘醇